As part of our ongoing series focussing on available medicines in Australia, we have added a product review of Daratumumab in the treatment of light chain (AL) amyloidosis.
This review discusses pharmacological properties, mechanism of action, drug interactions and major studies featuring Daratumumab. It also provides commentary and recommendations from Dr Hasib Sidiqi, a consultant haematologist at Fiona Stanley Hospital in Perth and an adjunct Associate Professor through Curtin Medical School.
Please login below to download this issue (PDF)